Fundamentals. Background: Although we&#8217;ve had more than a decade of experience with implanting drug-eluting stents, (DES), the best treatment for restenosis on these devices remains unknown. The drug-eluting balloons are a promising alternative which avoid the possibility of a new layer of metal on the restenotic injury. This study compared the performance of these balls<a href="https://solaci.org/en/2015/06/24/isar-desire-3-a-paclitaxel-eluting-balloon-versus-taxus-in-the-treatment-of-eluting-stent-restenosis/" title="Read more" >...</a>

Insides : 40%-60% of patients with acute coronary syndrome with non ST elevation (ACS) are treated clinically. Prasugrel proved superior to clopidogrel in patients with ACS undergoing invasive treatment (TRITON-TIMI 38). The TRILOGY ACS randomized multicenter trial assessed prasugrel and clopidogrel in patients with ACS treated clinically. Study results were neutral and have already been<a href="https://solaci.org/en/2015/06/24/trilogy-acs-prasugrel-versus-clopidogrel-in-patients-with-acute-coronary-syndromes-with-non-st-segment-elevation-treated-clinically-after-angiographic-evaluation/" title="Read more" >...</a>

Introduction: FAME study 2, presented at the European Congress of Cardiology 2012, is a multicenter study that randomized patients with stable angina FFR-guided angioplasty and optimal medical therapy versus optimal medical therapy alone. The study was stopped early due to a significantly higher rate of primary endpoints, (death, MI, or urgent revascularization), in the conservative<a href="https://solaci.org/en/2015/06/24/fame-2-cost-effectiveness-of-ffr-guided-angioplasty-in-patients-with-stable-angina/" title="Read more" >...</a>

This is the first trial that used autologous cardiac stem cells for the treatment of ischemic cardiomyopathy. It consecutively enrolled 37 patients with reduced ejection fraction (lower than 40%) before myocardial revascularization surgery. It was administered by intra coronary infusion and 17 were control subjects. In the group injected with stem cells, EF significantly improved<a href="https://solaci.org/en/2015/06/24/scipio-trial-intracoronary-infusion-of-autologous-cardiac-stem-cells-improve-ventricular-function/" title="Read more" >...</a>

In theory, also as for certain diseases caused by mineral deposits, Chelation treatment with EDTA (Ethylene Diamine Tetra-Acetic Acid) could reduce calcium and cholesterol content, and oxidative stress of plates. The placebo-controlled double blind design study included 1708, randomized to EDTA + vitamins, EDTA + placebo, placebo + vitamins o placebo + placebo. Primary end<a href="https://solaci.org/en/2015/06/24/tact-trial-chelation-therapy-for-the-treatment-of-coronary-disease/" title="Read more" >...</a>

High levels of HDL are known to exert a protective effect. In previous studies, dalcetrapib administration increased HDL 30% from baseline. The objective was to test dalcetrapib in the context of acute coronary syndrome (ACS). 15,871 ACS patients were randomized to receive dalcetrapib or placebo. Primary end point was cardiac death, myocardial infarction, ictus, new<a href="https://solaci.org/en/2015/06/24/dalcetrapib-dalcetrabib-for-the-treatment-of-acs/" title="Read more" >...</a>

The trial included 1,900 patients followed for at least 2 years, (mean 3.8 years), randomized 1:1 to pharmacological angioplasty stents, (sirolimus or paclitaxel at surgeon discretion), or CABG. We excluded acute coronary syndromes and left coronary trunk injury. The primary endpoint was death, myocardial infarction or stroke and the secondary main was the sum of<a href="https://solaci.org/en/2015/06/24/freedom-trial-cabg-versus-angioplasty-treatment-for-diabetic-patients-with-multivessel-disease/" title="Read more" >...</a>

Given the individual variability of response to antiplatelet therapies, measuring platelet function and designing tailored therapies could be beneficial. The ARTIC study tested the superiority of bedside platelet function monitoring with drug adjustment vs. the conventional post DES therapy without monitoring and drug adjustment. It included 2466 patients with stable coronary disease or Non-ST Elevation<a href="https://solaci.org/en/2015/06/24/artic-study-bedside-platelet-function-monitoring-to-reduce-events-after-des-implantation/" title="Read more" >...</a>

Coronary artery bypass grafting (CABG) without a cardiopulmonary bypass, (CBP), has increasingly become an alternative to the conventional standard (with pump). However, it is still controversial whether there is a decrease in morbidity and mortality between these two techniques. The aim of this study was to compare these two techniques in a high risk population.&nbsp;<a href="https://solaci.org/en/2015/06/24/prague-6-off-pump-versus-in-pump-cabg-in-high-risk-patients/" title="Read more" >...</a>

Background: Oral antiplatelet agents have a limitation in their duration of action and bioavailability. Cangrelor is an intravenous adenosine diphosphate (ADP) inhibitor that has a powerful effect, is rapid and reversible within one hour and with the advantage of intravenous administration that reduces variability in the bioavailability of the drug. The study was designed to<a href="https://solaci.org/en/2015/06/24/champion-phoenix-cangrelor-compared-with-clopidogrel-improves-efficiency-without-increasing-bleeding-in-patients-undergoing-angioplasty/" title="Read more" >...</a>